Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan.
Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patients. Updated data from the relapsed/refractory Mantle Cell Lymphoma cohort from the phase 1/2 ATALANTA-1 study is to be presented at a medical conference presentation 2nd half of 2025. The global MC...
Galapagos NV (NASDAQ:GLPG ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Paul Stoffels - Chair, Chief Executive Officer Thad Huston - Chief Operating, Chief Financial Officer John Mellors - Head of Cell Therapy Discovery WulfBöcher - Head of Immunology Omotayo Fasan - Clinical Program Head, Oncology Valeria Cnossen - Executive and General Counsel Glenn Schulma...
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Bo...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.